Tetracaine Hydrochloride

Manufacturer
NuCare Pharmaceuticals,Inc.
Effective date
2021-02-19
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-01 22:51:17

Label at a glance#

ProductTetracaine Hydrochloride
Active ingredientTETRACAINE HYDROCHLORIDE
Label structure15 sections

Indications and uses

Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.

Dosage and administration

One drop topically in the eye as needed.  Discard unused portion. Open package using standard aseptic technique.  The DROP‑TAINER ® dispenser may then be allowed to fall upon a sterile surface.  The entire outer surface of the DROP‑TAINER ® dispenser and its contents are sterile.

Storage and handling

Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI UNITS is supplied as single patient use 4 mL filled in 4mL natural medium or low density polyethylene plastic DROP TAINER dispensers and natural low density polyethylene tips with white polypropylene caps in a carton of 12.Each sterilized DROP TAINER dispenser is packaged in a clear PVC and Tyvek blister.This product does not contain a preservative; discard u...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Topical Administration

SPL UNCLASSIFIED SECTION

One drop topically in the eye as needed.  Discard unused portion.

2.2 Sterile Field Administration

SPL UNCLASSIFIED SECTION

Open package using standard aseptic technique.  The DROP‑TAINER ® dispenser may then be allowed to fall upon a sterile surface.  The entire outer surface of the DROP‑TAINER ® dispenser and its contents are sterile.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Sterile ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v.

4 CONTRAINDICATIONS SECTION

CONTRAINDICATIONS SECTION

None.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Corneal injury with Intracameral Use

SPL UNCLASSIFIED SECTION

Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine Hydrochloride Ophthalmic Solution 0.5% may lead to damage of the corneal endothelial cells.

5.2 Corneal Toxicity

SPL UNCLASSIFIED SECTION

Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage.

5.3 Corneal Injury due to Insensitivity

SPL UNCLASSIFIED SECTION

Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following serious ocular adverse reactions are described elsewhere in the labeling:

The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0.5%.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Ocular Adverse Reactions
Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary
There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women.  Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.

8.2 Lactation

LACTATION SECTION

Risk Summary
There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion.  The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0.5% or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential

SPL UNCLASSIFIED SECTION

No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution 0.5% on fertility are available.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety in the pediatric population has been demonstrated in clinical trials.  Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss.  Symptoms related to systemic toxicity consist mainly of effects on the neurologic and cardiovascular systems.

11 DESCRIPTION

DESCRIPTION SECTION

Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-,2-(dimethylamino) ethyl ester, monohydrochloride.  Its chemical formula is C 15H 24N 2O 2 • HCl and it is represented by the chemical structure:

Chemical Diagram
Chemical Diagram

Tetracaine hydrochloride is a fine, white, crystalline, odorless powder and has a molecular weight of 300.82.  Tetracaine Hydrochloride Ophthalmic Solution 0.5% has a pH of 3.7 to 5.5.

Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine)

Inactive ingredients: sodium chloride, sodium acetate trihydrate, acetic acid (to adjust pH approximately 4.5), Water for Injection, USP

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature.  Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride.

Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Topical administration of tetracaine hydrochloride ophthalmic solution results in localized temporary anesthesia.  The maximum effect is achieved within 10–20 seconds after instillation, with efficacy lasting 10–20 minutes.  Duration of effect can be extended with repeated dosing. [see Corneal toxicity (5.2) and Overdosage (10)] .

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI UNITS is supplied as single patient use 4 mL filled in 4mL natural medium or low density polyethylene plastic DROP TAINER dispensers and natural low density polyethylene tips with white polypropylene caps in a carton of 12.Each sterilized DROP TAINER dispenser is packaged in a clear PVC and Tyvek blister.This product does not contain a preservative; discard unused portion.

68071-5079-4 bottle of 4mL StorageStore at 2°C to 25°C (36°F to 77°F). Protect from light. Do not use if solution contains crystals is cloudy& or discolored.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Eye Care Precaution
Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive up to 20 minutes and that care should be taken to avoid accidental injuries.

ALCON ®
a Novartis company

Distributed by:
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
© 2016 Novartis

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

pdppdp

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
68071-5079-42024-06-19C16284748780-1ba0f9c33-145e-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® safely and effectively. See full prescribing information for Tetracaine Hydrochloride Ophthalmic Solution. Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® , topical ophthalmic Initial U.S. Approval: 1965
68071-5079-42023-01-30C16284748780-1ba0f9c33-145e-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® safely and effectively. See full prescribing information for Tetracaine Hydrochloride Ophthalmic Solution. Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® , topical ophthalmic Initial U.S. Approval: 1965
68071-5079-42021-02-19C16284748780-1ba0f9c33-145e-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® safely and effectively. See full prescribing information for Tetracaine Hydrochloride Ophthalmic Solution. Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® , topical ophthalmic Initial U.S. Approval: 1965
68071-5079-42021-01-29C16284748780-1ba0f9c33-145e-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® safely and effectively. See full prescribing information for Tetracaine Hydrochloride Ophthalmic Solution. Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT ® , topical ophthalmic Initial U.S. Approval: 1965

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0065-0741-12ML - Milliliter0065-07418dd61beb-f100-4e9d-a05b-1b036f9db54d12013-02-13
0065-0741-14ML - Milliliter0065-0741aaeddbd8-1c36-4b91-af31-25bf6c63a1dc12016-11-08

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68071-507968071-5079-4
0065-0741

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N208135-001TETRACAINE HYDROCHLORIDETETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-2984e616aacf4f…
2026-08-18 06:07:402026-07N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-2987673890dc5c…
2021-03-12 10:30 UTC2021-03N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-293f01610625f2…
2019-09-15 20:21 UTC2019-09N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29b00525d2431f…
2019-07-19 19:46 UTC2019-07N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-293f0d92c62455…
2023-05-13 08:27 UTC2023-05N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29053a50430f4f…
2023-01-26 05:58 UTC2023-01N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N208135-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2016-02-29f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
1b46ab55-2072-d3a9-e063-6294a90a9ccc947d7944-afe9-5361-e053-2995a90a05e92024-06-19Warnings, Adverse reactionsExact identifier
spl set id: 947d7944-afe9-5361-e053-2995a90a05e9
Tetracaine HydrochlorideTETRACAINE HYDROCHLORIDEAlcon Laboratories, Inc.5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba792024-01-19Warnings, Adverse reactionsExact identifier
ndc (product): 0065-0741

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.